Table 3 Prognostic value of CALN1 methylation percentage for intravesical recurrence of bladder cancer
From: CALN1 hypomethylation as a biomarker for high-risk bladder cancer
Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
HRa (95% CIb) | P | HR (95% CI) | P | |
CALN1 methylation percentage | 0.98 (0.97–1.00) | 0.011 | 0.98 (0.97–1.00) | 0.018 |
Age | 1.03 (0.99–1.09) | 0.15 | ||
Sex (male) | 0.63 (0.25–1.60) | 0.33 | ||
Smoking history (yes) | 0.50 (0.23–1.11) | 0.087 | ||
BCGc therapy (yes) | 0.41 (0.10–1.75) | 0.23 | ||
Stage (Ta) | 0.56 (0.24–1.32) | 0.19 | ||
Grade (low) | 0.63 (0.25–1.61) | 0.34 | ||
Number (single) | 1.02 (0.47–2.26) | 0.95 | ||
Size (≥ 30 mm) | 4.25 (1.50–12.1) | 0.0065 | 3.75 (1.33–10.6) | 0.012 |
Recurrent tumor | 0.84 (0.38–1.88) | 0.68 | ||